JCR Pharmaceuticals Co (TSE:4552) Cyclically Adjusted Revenue per Share: 円278.74 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4552 JCR Pharmaceuticals Co Ltd TSE:4552
46 GF Score
Price 円528.00
GF Value 円787.71
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is JCR Pharmaceuticals Co Cyclically Adjusted Revenue per Share?

JCR Pharmaceuticals Co TSE:4552 +0.57% 46 Cyclically Adjusted Revenue per Share is 円278.74 as of Mar. 2026. GuruFocus rates TSE:4552 with a GF Score™ of 46/100 and a GF Value™ of 円787.71 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

JCR Pharmaceuticals Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円81.723. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円278.74 for the trailing ten years ended in Mar. 2026.

During the past 12 months, JCR Pharmaceuticals Co's average Cyclically Adjusted Revenue Growth Rate was 8.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of JCR Pharmaceuticals Co was 14.90% per year. The lowest was 6.40% per year. And the median was 11.10% per year.

As of today (2026-09-07), JCR Pharmaceuticals Co's current stock price is 円528.00. JCR Pharmaceuticals Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円278.74. JCR Pharmaceuticals Co's Cyclically Adjusted PS Ratio of today is 1.89.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of JCR Pharmaceuticals Co was 24.79. The lowest was 1.60. And the median was 10.14.


JCR Pharmaceuticals Co  (TSE:4552) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

JCR Pharmaceuticals Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=528.00/278.74
=1.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of JCR Pharmaceuticals Co was 24.79. The lowest was 1.60. And the median was 10.14.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


JCR Pharmaceuticals Co Cyclically Adjusted Revenue per Share Related Terms


JCR Pharmaceuticals Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for JCR Pharmaceuticals Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JCR Pharmaceuticals Co Cyclically Adjusted Revenue per Share Chart

JCR Pharmaceuticals Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 189.08 210.80 237.13 257.75 278.74

JCR Pharmaceuticals Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 262.20 269.30 275.24 278.74 0.00

TSE:4552 vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, JCR Pharmaceuticals Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JCR Pharmaceuticals Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JCR Pharmaceuticals Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where JCR Pharmaceuticals Co's Cyclically Adjusted PS Ratio falls into.


TSE:4552
46GF Score
JCR Pharmaceuticals Co Ltd TSE:4552
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JCR Pharmaceuticals Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, JCR Pharmaceuticals Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=81.723/112.7000*112.7000
=81.723

Current CPI (Mar. 2026) = 112.7000.

JCR Pharmaceuticals Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 29.836 98.100 34.276
201609 37.224 98.000 42.808
201612 35.966 98.400 41.193
201703 39.227 98.100 45.065
201706 34.578 98.500 39.563
201709 46.000 98.800 52.472
201712 40.870 99.400 46.339
201803 43.155 99.200 49.028
201806 37.897 99.200 43.054
201809 45.095 99.900 50.873
201812 42.366 99.700 47.890
201903 61.570 99.700 69.598
201906 41.666 99.800 47.052
201909 48.990 100.100 55.157
201912 55.143 100.500 61.837
202003 53.957 100.300 60.628
202006 41.745 99.900 47.094
202009 46.525 99.900 52.486
202012 68.226 99.300 77.433
202103 85.884 99.900 96.888
202106 79.042 99.500 89.528
202109 149.505 100.100 168.324
202112 95.667 100.100 107.709
202203 87.052 101.100 97.040
202206 77.382 101.800 85.667
202209 48.015 103.100 52.486
202212 88.526 104.100 95.839
202303 61.109 104.400 65.967
202306 86.262 105.200 92.412
202309 107.327 106.200 113.896
202312 75.355 106.800 79.518
202403 72.958 107.200 76.701
202406 65.241 108.200 67.954
202409 68.090 108.900 70.466
202412 74.136 110.700 75.475
202503 58.082 111.100 58.918
202506 67.349 111.700 67.952
202509 104.945 112.000 105.601
202512 73.722 113.000 73.526
202603 81.723 112.700 81.723

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円278.74 mean?
JCR Pharmaceuticals Co (TSE:4552) has a Cyclically Adjusted Revenue per Share of 円278.74 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on JCR Pharmaceuticals Co and its competitors.
Is JCR Pharmaceuticals Co's Cyclically Adjusted Revenue per Share too high?
JCR Pharmaceuticals Co's current Cyclically Adjusted Revenue per Share is 円278.74. Overall, JCR Pharmaceuticals Co has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JCR Pharmaceuticals Co's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
JCR Pharmaceuticals Co's Cyclically Adjusted Revenue per Share of 円278.74 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on JCR Pharmaceuticals Co and its competitors. JCR Pharmaceuticals Co's current Cyclically Adjusted Revenue per Share is 円278.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JCR Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co (TSE:4552) is currently considered Possible Value Trap. The stock's GF Value™ is 円787.71, compared to a current price of 円528.00 — trading 33% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円278.74. JCR Pharmaceuticals Co's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For JCR Pharmaceuticals Co (TSE:4552), the current Cyclically Adjusted Revenue per Share is 円278.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JCR Pharmaceuticals Co (TSE:4552) Overvalued in 2026?

Based on GuruFocus' analysis, JCR Pharmaceuticals Co stock appears to be undervalued. The current stock price of 円528.00 is trading 33% below its estimated GF Value™ of 円787.71. GuruFocus considers JCR Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for TSE:4552:

  • Cyclically Adjusted Revenue per Share: 円278.74
  • GF Value™: 円787.71 vs. price of 円528.00 (33% below fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the TSE:4552 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


JCR Pharmaceuticals Co Business Description

Other Exchanges JCRRF:USA
Address 3-19 Kasuga-cho, Ashiya, Hyogo, JPN, 659-0021
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.
46GF Score

Get the complete analysis for TSE:4552

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円528.00
Price
円787.71
GF Value